STI-6991 / Sorrento - LARVOL DELTA

Sorrento launches novel I-Cell COVID-19 cellular vaccine program (GlobeNewswire) - "Sorrento Therapeutics, Inc...announced it has been working on a novel decoy cellular vaccine for COVID-19 (STI-6991) and is in active discussions with the FDA’s Center for Biologics Evaluation and Research under IND#019724 regarding the required IND-enabling studies, CMC (chemistry, manufacturing and controls), clinical protocol and end-points for potential accelerated approval. Upon receiving guidance from the FDA, Sorrento intends to submit a full package for an IND filing that would enable human clinical trials to start as soon as possible....Sorrento believes it may be in a position to initiate human vaccination trials as early as mid-year 2020."

Clinical • IND • New trial

Sorrento Launches Novel I-Cell COVID-19 Cellular Vaccine Program (GlobeNewswire, Sorrento Therapeutics, Inc.) - "STI-6991 is an I-Cell^TM COVID-19 cellular vaccine made of replication-deficient human erythroleukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virus....The I-Cell vaccine is expected to elicit both T cell and B cell immunities against SARS-CoV-2."

Clinical